

Form 51-102F3
MATERIAL CHANGE REPORT

1. **Name and address of the Company.**

CHROMEDX CORP. (the “Company”)
65 Queen Street West
Suite 520
Toronto, Ontario M5H 2M5

2. **Date of Material Change.**

October 14, 2015

3. **News Release.**

Press release disclosing the material change was released on October 16, 2015, through the facilities of Newsfile Corp.

4. **Summary of Material Change.**

The Company announced that it had completed the first tranche of its previously announced non-brokered private placement (the “**Offering**”) for gross proceeds of CDN\$350,000 through the issuance of 1,750,000 units (each a “**Unit**”) at a price of CDN\$0.20 per Unit. Each Unit is comprised of one common share of the Company (a “**Common Share**”) and one Common Share purchase warrant (a “**Warrant**”), each Warrant entitling the holder thereof to acquire one Common Share at a price of \$0.30 for a period of twenty-four (24) months from the closing date.

The Company will use the net proceeds from the sale of the Units for developing prototypes, marketing and general working capital purposes.

5. **Full Description of Material Change.**

The material change is fully described in the Company’s press release which is attached as Schedule “A”.

6. **Reliance on subsection 7.1(2) or (3) of National Instrument 51-102.**

The report is not being filed on a confidential basis.

7. **Omitted Information.**

No significant facts have been omitted from this Material Change Report.

8. **Executive Officer.**

Wayne Maddever, Chief Executive Officer.

9. **Date of Report.**

This report is dated at Toronto, this 19th day of October, 2015.

CHROMEDX CORP.

Per: _____
Wayne Maddever, CEO

Schedule "A"

CHROMEDX CORP. ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

TORONTO, ONTARIO – October 15, 2015 – ChroMedX Corp. (the “**Company**”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it has completed the first tranche of its previously announced non-brokered private placement (the “**Offering**”), pursuant to which the Company issued and sold an aggregate of 1,750,000 units (each, a “**Unit**”) of the Company at a price of CDN\$0.20 per Unit for aggregate gross proceeds of CDN\$350,000. Each Unit is comprised of one common share of the Company (a “**Common Share**”) and one Common Share purchase warrant (a “**Warrant**”), each Warrant entitling the holder thereof to acquire one Common Share at a price of \$0.30 for a period of twenty-four (24) months from the closing date.

In connection with the Offering, the Company also paid an aggregate of \$28,000 in cash commissions and has issued 140,000 broker warrants (“**Broker Warrants**”) to certain parties for introducing purchasers to the Company. Each Broker Warrant entitles the holder thereof to purchase one Common Share at a price of CDN\$0.30 for a period of 24 months from the closing date.

The securities issued in connection with the Offering will have a four month and one day hold period pursuant to applicable securities laws.

About ChroMedX Corp.

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:

Website: www.chromedx.com

Facebook: facebook.com/ChroMedXcorp

Twitter: www.twitter.com/ChroMedXcorp

Investor Relations:

Shawn Overton

d. 647-528-9344

o. 647-872-9982 ext. 2

TF. 1-844-247-6633 ext. 2

soverton@ChroMedX.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com.